CNI Screen

CNI Cancer Evaluation Test

The Chronix Biomedical CNI Screen blood test is a vast improvement to more traditional methods of determining the presence of cancer. The essential difference is that now for the first time, using proprietary Next Generation Sequencing we can detect cancer mutations of DNA in blood plasma. Our method is based on years long development using proprietary technologies and sophisticated and detailed comparisons to our database of healthy individuals. This enables a sensitive and specific distinction of normal variances from cfDNA that is of high risk to be coming from a malignancy. Advantages of this new technology, are that we can now look at the entirety of the body and its health state relating to cancer. Current scanning and tissue biopsy can only look at a specific part of the body, such as the lung or prostate, and is usually only carried out on presentation of symptoms.

laboratory
laboratory

CNI Second Opinion™ Prostate Cancer Evaluation Test

It has recently been found that mutated DNA fragments from cancer cells find their way into the bloodstream. They can be detected by next generation sequencing – the technique that has successfully mapped the whole human genome. Prostate cancer mutations tend to produce “hot spots” (gains and losses) in the mutated DNA fragments that are in the blood. The reasons are currently under investigation. Nonetheless, DNA from the cancer cells is detectable in your bloodstream. The Chronix Second Opinion™ prostate cancer evaluation searches for these sequences and identifies them.

CNI Second Opinion™ Breast Cancer Evaluation Test

Chronix Biomedical has made available a laboratory developed test for the detection of risk factors highly associated with Breast cancer. Through the simple process of drawing blood, we can now offer a test than can with a high degree of accuracy, detect macromolecular mutations of DNA fragments in blood plasma, which are closely associated with Breast cancer. The Chronix Biomedical Second Opinion™ Breast Cancer Evaluation blood test was designed to be a supplemental test for women with abnormal mammograms or detectable lumps.

laboratory
blood

CNI Monitor

Treatment Monitoring Test

The Chronix Biomedical CNI Monitor blood test is a vast improvement over the current methods of determining whether a patient is responding to therapy or not. Chemotherapies are based on standard regimens, which might not work best for an individual patient. Often the response to chemotherapy can not be assessed real time, which lead to a lack of efficacy only seen after the end of therapy by e.g. imaging. We now can provide real-time measurements of cancer load, which can help to modify the treatment towards a better working regimen (combination of drugs) earlier.

Patient Consent

Please note, that Chronix tests are known as „Laboratory developed tests” that doctors use to help make medical decisions. There is a Chance of false positive and false negative results. A patient taking blood sample of our tests must be aware of this statement and sign a Consent Form.

Different outcome scenarios as result of the CNI score